Engineered CAR-T Cells Boost STING Therapy in Pancreatic Cancer : Gastroenterology | Jul 2026

Introduction:

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies but has achieved limited success in solid tumors such as pancreatic cancer. Major barriers include T-cell exhaustion, poor persistence within tumors, and a profoundly immunosuppressive tumor microenvironment. Novel approaches that enhance CAR-T cell activity while simultaneously remodeling the tumor microenvironment are urgently needed.

Problem Statement:

STING agonists can stimulate antitumor immunity and inflame the tumor microenvironment, making them attractive partners for CAR-T therapy. However, activation of STING signaling within T cells themselves may impair CAR-T cell function, potentially limiting the effectiveness of this combination strategy. Understanding how to exploit STING activation while avoiding its detrimental effects on T cells is critical for advancing cellular therapies in pancreatic cancer.

Summary:

This study demonstrates a novel strategy to enhance CAR-T cell therapy in pancreatic cancer by genetically eliminating STING signaling within CAR-T cells while simultaneously administering a STING agonist. The combination resulted in superior tumor cell killing, increased CAR-T cell proliferation, reduced T-cell exhaustion, and expansion of long-lived effector-memory T cells. Mechanistic analyses revealed that the therapeutic benefit depended on preserving STING activation within cancer cells while preventing STING-mediated dysfunction in CAR-T cells. The investigators identified a positive feedback loop involving interferon-γ and tumor necrosis factor released by CAR-T cells, which enhanced tumor-cell STING signaling and further strengthened antitumor immune responses. This reciprocal interaction improved CAR-T cell fitness and amplified tumor destruction. In both xenograft and syngeneic pancreatic cancer models, STING-deficient CAR-T cells combined with the STING agonist diABZI achieved superior tumor control compared with either strategy alone. Enhanced efficacy was accompanied by increased intratumoral CAR-T cell accumulation and favorable remodeling of the tumor microenvironment. These findings provide compelling preclinical evidence that selective manipulation of STING signaling can overcome key obstacles limiting CAR-T therapy in solid tumors. The study introduces a potentially transformative strategy for pancreatic cancer and suggests that engineering CAR-T cells to resist intrinsic STING activation may unlock the full therapeutic potential of STING agonists in immune-resistant malignancies.